Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 1, 2001, Pages 41-48

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Galbreath, Robert W ^a,c   Lief, Jonathan H ^a,c  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

103Pd; 125I; Biochemical outcome; Brachytherapy; Prostate cancer

Indexed keywords

IMPLANTS (SURGICAL); IODINE; PALLADIUM; RADIOISOTOPES; RADIOTHERAPY; TUMORS;

PROSTATE BRACHYTHERAPY;

ONCOLOGY;

IODINE 125; PALLADIUM 103;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PALLADIUM; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0035450623     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01594-2     Document Type: Article

References (30)

1. Is brachytherapy comparable with radical prostatectomy and external beam radiation for clinically localized prostate cancer?
2. Palladium-103 brachytherapy for prostate carcinoma
3. Modern prostate brachytherapy: Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
4. Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques
5. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma
6. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma
7. Five-year biochemical outcome, and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer
8. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
9. Five-year biochemical outcome after prostate brachytherapy for hormone-naive men ≤ 62 years of age
10. Seed fixity in the prostate/periprostatic region following brachytherapy
11. Consensus Statement: Guidelines for PSA following radiation therapy
12. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection
13. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy CommitteeTask Group No. 43
14. Comparison of seed loading approaches in prostate brachytherapy
15. Potential role of various dosimetric quality indicators in prostate brachytherapy
16. Rectal dosimetric analysis following prostatic conformal brachytherapy
17. The influence of timing on the dosimetric analysis of transperineal ultrasound guided prostatic conformal brachytherapy
18. The effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation
19. The influence of prophylactic dexamethasone on edema following prostate brachytherapy
20. Quality assurance calibration of I-125 rapid strand in a sterile environment
21. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
22. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
23. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease
24. Prostate cancer in men age 50 years or younger: A review of the department of defense center for prostate disease research multi-center prostate cancer database
25. Age related prostate cancer metastases
26. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trials
27. A dose response study for I-125 prostate implants
28. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition